2020 Q1 Form 10-Q Financial Statement
#000143774920010278 Filed on May 11, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 | 2018 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.390M | $1.200M | $1.420M |
| YoY Change | 15.83% | -20.0% | 10.94% |
| % of Gross Profit | |||
| Research & Development | $1.534M | $1.700M | $1.370M |
| YoY Change | -9.73% | -6.89% | 20.18% |
| % of Gross Profit | |||
| Depreciation & Amortization | $27.02K | $18.27K | $30.00K |
| YoY Change | 47.88% | -34.78% | 0.0% |
| % of Gross Profit | |||
| Operating Expenses | $1.534M | $1.700M | $2.820M |
| YoY Change | -9.73% | -6.89% | 15.1% |
| Operating Profit | $2.955M | -$2.919M | |
| YoY Change | -201.25% | -12.91% | |
| Interest Expense | -$34.10K | $20.68K | $30.00K |
| YoY Change | -264.86% | -44.79% | -99.06% |
| % of Operating Profit | -1.15% | ||
| Other Income/Expense, Net | $0.00 | ||
| YoY Change | |||
| Pretax Income | -$2.921M | -$2.898M | -$5.530M |
| YoY Change | 0.79% | -12.55% | -857.53% |
| Income Tax | -$362.4K | -$150.4K | -$50.00K |
| % Of Pretax Income | |||
| Net Earnings | -$2.559M | -$2.748M | -$5.570M |
| YoY Change | -6.88% | -17.08% | -411.17% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.07 | -$0.81 | |
| Diluted Earnings Per Share | $34.51M | $3.376M | -$1.633M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 34.60M | 3.379M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 | 2018 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $10.83M | $5.330M | $7.990M |
| YoY Change | 103.19% | -67.1% | -10.22% |
| Cash & Equivalents | $10.83M | $5.334M | $7.991M |
| Short-Term Investments | |||
| Other Short-Term Assets | $890.0K | $1.050M | $920.0K |
| YoY Change | -15.24% | 17.98% | 19.48% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $11.72M | $6.384M | $8.914M |
| YoY Change | 83.54% | -62.65% | -7.78% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $225.3K | $332.0K | $350.3K |
| YoY Change | -32.13% | -23.26% | -23.96% |
| Goodwill | $0.00 | ||
| YoY Change | -100.0% | ||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $252.6K | $319.7K | $298.5K |
| YoY Change | -21.01% | 15.96% | -33.74% |
| Total Long-Term Assets | $9.341M | $9.604M | $9.288M |
| YoY Change | -2.74% | -40.99% | -43.64% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $11.72M | $6.384M | $8.914M |
| Total Long-Term Assets | $9.341M | $9.604M | $9.288M |
| Total Assets | $21.06M | $15.99M | $18.20M |
| YoY Change | 31.71% | -52.08% | -30.38% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $655.3K | $480.0K | $198.8K |
| YoY Change | 36.52% | 14.53% | -61.17% |
| Accrued Expenses | $630.0K | $710.0K | $610.0K |
| YoY Change | -11.27% | 57.78% | -62.58% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | -100.0% | ||
| Total Short-Term Liabilities | $1.287M | $1.193M | $804.0K |
| YoY Change | 7.82% | -16.12% | -70.12% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $110.0K | $200.0K | |
| YoY Change | -45.0% | ||
| Total Long-Term Liabilities | $110.0K | $200.0K | $0.00 |
| YoY Change | -45.0% | -100.0% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.287M | $1.193M | $804.0K |
| Total Long-Term Liabilities | $110.0K | $200.0K | $0.00 |
| Total Liabilities | $3.156M | $3.033M | $2.590M |
| YoY Change | 4.04% | -16.83% | -47.3% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$94.28M | -$82.67M | -$79.92M |
| YoY Change | 14.04% | 27.45% | 29.84% |
| Common Stock | $112.2M | $95.63M | $95.54M |
| YoY Change | 17.31% | 1.1% | 15.4% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $17.90M | $12.95M | $15.61M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $21.06M | $15.99M | $18.20M |
| YoY Change | 31.71% | -52.08% | -30.38% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 | 2018 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.559M | -$2.748M | -$5.570M |
| YoY Change | -6.88% | -17.08% | -411.17% |
| Depreciation, Depletion And Amortization | $27.02K | $18.27K | $30.00K |
| YoY Change | 47.88% | -34.78% | 0.0% |
| Cash From Operating Activities | -$3.504M | -$2.657M | -$3.020M |
| YoY Change | 31.87% | -19.21% | 32.46% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | ||
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | ||
| YoY Change | -100.0% | ||
| Cash From Investing Activities | $0.00 | ||
| YoY Change | -100.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 155.2K | 0.000 | |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -3.504M | -2.657M | -3.020M |
| Cash From Investing Activities | 0.000 | ||
| Cash From Financing Activities | 155.2K | 0.000 | |
| Net Change In Cash | -3.349M | -2.657M | -3.020M |
| YoY Change | 26.03% | -136.39% | -139.32% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$3.504M | -$2.657M | -$3.020M |
| Capital Expenditures | $0.00 | ||
| Free Cash Flow | -$3.020M | ||
| YoY Change | 33.04% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | dffn |
Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
|
9100 | |
| CY2019Q4 | dffn |
Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
|
57378 | |
| CY2020Q1 | dffn |
Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
|
1124071 | |
| CY2020Q1 | dffn |
Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
|
0 | |
| CY2020Q1 | dffn |
Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
|
258627 | |
| CY2019Q1 | dffn |
Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
|
28549 | |
| CY2020Q1 | dffn |
Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
|
888234 | |
| CY2019Q4 | dffn |
Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
|
472464 | |
| CY2020Q1 | dffn |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
134798 | |
| CY2020Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
655298 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1251412 | |
| CY2020Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
338627 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
48338 | |
| CY2020Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
149620 | |
| CY2019Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
182708 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
112149913 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
111824859 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
91204 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
191380 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
191380 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
91204 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22541799 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2343069 | |
| CY2020Q1 | us-gaap |
Assets
Assets
|
21057126 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
24110523 | |
| CY2020Q1 | us-gaap |
Assets Current
AssetsCurrent
|
11716462 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
14649813 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
346030 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
119644 | |
| CY2020Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
8639000 | |
| CY2019Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
8639000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14177349 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10828228 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
7991172 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5333714 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-3349121 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2657458 | |
| CY2020Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.35 | |
| CY2020Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
21261070 | |
| CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
34604436 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
33480365 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
34604436 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
33480365 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
34605 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
33481 | |
| CY2020Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-362380 | |
| CY2019Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-150352 | |
| CY2020Q1 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
1756894 | |
| CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
2119274 | |
| CY2020Q1 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
17000 | |
| CY2019Q1 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
18000 | |
| CY2020Q1 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.04 | |
| CY2020Q1 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
0.9 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
27020 | |
| CY2019Q1 | us-gaap |
Depreciation
Depreciation
|
18272 | |
| CY2020Q1 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
27020 | |
| CY2019Q1 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
18272 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.07 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.81 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
34507496 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
3376230 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1393808 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1200728 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2921195 | |
| CY2019Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2898161 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-362380 | |
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-150352 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-455489 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
250871 | |
| CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
223757 | |
| CY2020Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
34100 | |
| CY2019Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
20684 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.1 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
245945 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
39735 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
118519 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
87691 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
22188 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P2Y109D | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
| CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
3155501 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
3976261 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
21057126 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
24110523 | |
| CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1286820 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1721421 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Organization and Description of Business</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), a Delaware corporation, is a clinical stage biotechnology company developing new treatments for life-threatening conditions by improving the body’s ability to bring oxygen to the areas where it is needed most. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (“TSC”), for use in those life-threatening conditions in which cellular oxygen deprivation (“hypoxia”) is the basis for significant unmet medical needs. TSC is designed to safely and selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in many indications, including stroke, oncology and cardiovascular disease. In stroke, TSC helps promote the diffusion of oxygen into those brain cells in which oxygen-deprivation causes neuronal death resulting in patient mortality or morbidity. In cancer, TSC re-oxygenates treatment-resistant cancerous tissue, making the cancer cells up to <div style="display: inline; font-style: italic; font: inherit;">three</div> times more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. In addition to the TSC programs, the Company is exploring alternatives regarding how best to capitalize upon our product candidate RES-<div style="display: inline; font-style: italic; font: inherit;">529,</div> which <div style="display: inline; font-style: italic; font: inherit;"> may </div>include possible out-licensing and other options. RES-<div style="display: inline; font-style: italic; font: inherit;">529</div> is a novel <div style="display: inline; font-style: italic; font: inherit;">PI3K/Akt/mTOR</div> pathway inhibitor which has completed <div style="display: inline; font-style: italic; font: inherit;">two</div> Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically GBM. RES-<div style="display: inline; font-style: italic; font: inherit;">529</div> has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and capable of crossing the blood brain barrier.</div></div> | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
155193 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
||
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3504314 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2657458 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2558815 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2747809 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2955295 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2918845 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
30000 | |
| CY2019Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
20000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
223757 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
100000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
111970 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
111477 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
200000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
111787 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
135566 | |
| CY2020Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
519552 | |
| CY2019Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
||
| CY2020Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
225346 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
252366 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1534467 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1699845 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-94282893 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-91724078 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
247043 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
358532 | |
| CY2020Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
252561 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
322301 | |
| CY2020Q1 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
22205 | |
| CY2019Q4 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
70108 | |
| CY2020Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
238232 | |
| CY2019Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
||
| CY2020Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
393425 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
||
| CY2019Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
334205 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
191380 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
91204 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
||
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.137 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.017 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
560524 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
30.60 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
147 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
873500 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.36 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
||
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
309276 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1182629 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
55.78 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.91 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
142.50 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.47 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y255D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
||
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y73D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
200000 | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
200000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17901625 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20134262 | |
| CY2018Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
15611559 | |
| CY2019Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
12954954 | |
| CY2019Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
20134262 | |
| CY2020Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
17901625 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:44pt;">The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. The full extent to which the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that <div style="display: inline; font-style: italic; font: inherit;"> may </div>emerge concerning COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> and the actions taken to contain it or treat COVID-<div style="display: inline; font-style: italic; font: inherit;">19,</div> as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> within our financial statements and there <div style="display: inline; font-style: italic; font: inherit;"> may </div>be changes to those estimates in future periods. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, actual results <div style="display: inline; font-style: italic; font: inherit;"> may </div>materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined necessary.</div></div></div></div> |
